LifeArc, an independent medical research charity, announces the appointment of Clare Terlouw as its new Head of LifeArc Ventures, effective immediately.

In this role, Clare will be responsible for developing and implementing a strategy for LifeArc’s investments across the life science sector, enhancing our commitment to funding the translation of promising life sciences research. LifeArc’s strategic investments in innovation are a key component of its charitable model, supporting both its ability to create impact for the benefit of patients and aims to contribute to its long-term sustainability.

LifeArc CEO Dr Melanie Lee said: “LifeArc plays a vital role in advancing medical research by providing the funds, advice and scientific expertise to translate early stage innovation. Clare joins LifeArc at an exciting time as we set out our plans to maximise the benefit we create for patients. Her financing and sector knowledge will help us optimise the return and impact of our investments”.

Clare was most recently at Syncona Investment Management Ltd, a FTSE250 healthcare investment trust, where she was Head of Corporate Development. She is a highly experienced and respected life sciences corporate finance and investment specialist, with significant expertise in growth funding for innovative life sciences companies in the private and public markets. Clare is also a board member of the BioIndustry Association and a non-executive director of Stevenage Bioscience Catalyst.


Media contacts
Janet Morgan or Surinder Maan
Mobile: 07889 591935 or 07970293826

Notes to editors

About LifeArc

LifeArc is a self-funded medical research charity. Our mission is to advance translation of early science into health care treatments or diagnostics that can be taken through to full development and made available to patients. We have been doing this for more than 25 years and our work has resulted in a diagnostic for antibiotic resistance and four licensed medicines.

Our success allows us to explore new approaches to stimulate and fund translation. We have our own drug discovery and diagnostics development facilities, supported by experts in technology transfer and intellectual property who also provide services to other organisations. Our model is built on collaboration, and we partner with a broad range of groups including medical research charities, research organisations, industry, and academic scientists. We are motivated by patient need and scientific opportunity.

Two funds help us to invest in external projects for the benefit of patients: our Philanthropic Fund provides grants to support medical research projects focused on the translation of rare diseases research and our Seed Fund is aimed at start-up companies focused on developing new therapeutics and biological modalities. Follow us on LinkedIn or Twitter